Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1989 1
1990 3
1991 1
1992 1
1993 2
1995 1
1996 3
1997 4
1998 2
1999 2
2001 4
2002 2
2003 7
2004 10
2005 9
2006 1
2007 4
2008 6
2009 3
2010 3
2011 4
2012 9
2013 11
2014 13
2015 12
2016 11
2017 13
2018 12
2019 24
2020 33
2021 33
2022 46
2023 33
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

305 results

Results by year

Filters applied: . Clear all
Page 1
Non-viral precision T cell receptor replacement for personalized cell therapy.
Foy SP, Jacoby K, Bota DA, Hunter T, Pan Z, Stawiski E, Ma Y, Lu W, Peng S, Wang CL, Yuen B, Dalmas O, Heeringa K, Sennino B, Conroy A, Bethune MT, Mende I, White W, Kukreja M, Gunturu S, Humphrey E, Hussaini A, An D, Litterman AJ, Quach BB, Ng AHC, Lu Y, Smith C, Campbell KM, Anaya D, Skrdlant L, Huang EY, Mendoza V, Mathur J, Dengler L, Purandare B, Moot R, Yi MC, Funke R, Sibley A, Stallings-Schmitt T, Oh DY, Chmielowski B, Abedi M, Yuan Y, Sosman JA, Lee SM, Schoenfeld AJ, Baltimore D, Heath JR, Franzusoff A, Ribas A, Rao AV, Mandl SJ. Foy SP, et al. Among authors: abedi m. Nature. 2023 Mar;615(7953):687-696. doi: 10.1038/s41586-022-05531-1. Epub 2022 Nov 10. Nature. 2023. PMID: 36356599 Free PMC article. Clinical Trial.
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.
Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Park JH, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Feng C, Dong J, Shen T, Milletti F, Rossi JM, Vezan R, Masouleh BK, Houot R. Shah BD, et al. Among authors: abedi m. Lancet. 2021 Aug 7;398(10299):491-502. doi: 10.1016/S0140-6736(21)01222-8. Epub 2021 Jun 4. Lancet. 2021. PMID: 34097852 Clinical Trial.
Ultrasound-controllable engineered bacteria for cancer immunotherapy.
Abedi MH, Yao MS, Mittelstein DR, Bar-Zion A, Swift MB, Lee-Gosselin A, Barturen-Larrea P, Buss MT, Shapiro MG. Abedi MH, et al. Nat Commun. 2022 Mar 24;13(1):1585. doi: 10.1038/s41467-022-29065-2. Nat Commun. 2022. PMID: 35332124 Free PMC article.
Gene therapy clinical trials worldwide to 2017: An update.
Ginn SL, Amaya AK, Alexander IE, Edelstein M, Abedi MR. Ginn SL, et al. Among authors: abedi mr. J Gene Med. 2018 May;20(5):e3015. doi: 10.1002/jgm.3015. Epub 2018 Apr 19. J Gene Med. 2018. PMID: 29575374 Review.
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.
Shah BD, Bishop MR, Oluwole OO, Logan AC, Baer MR, Donnellan WB, O'Dwyer KM, Holmes H, Arellano ML, Ghobadi A, Pagel JM, Lin Y, Cassaday RD, Park JH, Abedi M, Castro JE, DeAngelo DJ, Malone AK, Mawad R, Schiller GJ, Rossi JM, Bot A, Shen T, Goyal L, Jain RK, Vezan R, Wierda WG. Shah BD, et al. Among authors: abedi m. Blood. 2021 Jul 8;138(1):11-22. doi: 10.1182/blood.2020009098. Blood. 2021. PMID: 33827116 Free PMC article. Clinical Trial.
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study.
Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Park JH, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Dong J, Adhikary S, Zhou L, Schuberth PC, Faghmous I, Masouleh BK, Houot R. Shah BD, et al. Among authors: abedi m. J Hematol Oncol. 2022 Dec 10;15(1):170. doi: 10.1186/s13045-022-01379-0. J Hematol Oncol. 2022. PMID: 36494725 Free PMC article.
Biomolecular Ultrasound and Sonogenetics.
Maresca D, Lakshmanan A, Abedi M, Bar-Zion A, Farhadi A, Lu GJ, Szablowski JO, Wu D, Yoo S, Shapiro MG. Maresca D, et al. Among authors: abedi m. Annu Rev Chem Biomol Eng. 2018 Jun 7;9:229-252. doi: 10.1146/annurev-chembioeng-060817-084034. Epub 2018 Mar 26. Annu Rev Chem Biomol Eng. 2018. PMID: 29579400 Free PMC article. Review.
Designed Endocytosis-Triggering Proteins mediate Targeted Degradation.
Huang B, Abedi M, Ahn G, Coventry B, Sappington I, Wang R, Schlichthaerle T, Zhang JZ, Wang Y, Goreshnik I, Chiu CW, Chazin-Gray A, Chan S, Gerben S, Murray A, Wang S, O'Neill J, Yeh R, Misquith A, Wolf A, Tomasovic LM, Piraner DI, Gonzalez MJD, Bennett NR, Venkatesh P, Satoe D, Ahlrichs M, Dobbins C, Yang W, Wang X, Vafeados D, Mout R, Shivaei S, Cao L, Carter L, Stewart L, Spangler JB, Bernardes GJL, Roybal KT, Greisen P Jr, Li X, Bertozzi C, Baker D. Huang B, et al. Among authors: abedi m. bioRxiv [Preprint]. 2023 Sep 20:2023.08.19.553321. doi: 10.1101/2023.08.19.553321. bioRxiv. 2023. PMID: 37781607 Free PMC article. Preprint.
Lip print enhancement: review.
Abedi M, Afoakwah C, Bonsu DNOM. Abedi M, et al. Forensic Sci Res. 2020 May 5;7(1):24-28. doi: 10.1080/20961790.2020.1751396. eCollection 2022. Forensic Sci Res. 2020. PMID: 35341131 Free PMC article. Review.
305 results